Updated:
GT Biopharma, Inc.
GT Biopharma, Inc. was founded in 1997 and is headquartered in San Francisco, California. The company operates as a clinical-stage biotechnology firm, with CEO...
GT Biopharma, Inc.
GT Biopharma, Inc. was founded in 1997 and is headquartered in San Francisco, California. The company operates as a clinical-stage biotechnology firm, with CEO Anthony Cataldo leading from 2011 onward. Its wealth origin is not publicly disclosed. The firm's strategy centers on immuno-oncology, specifically NK cell-directed therapies. Their lead candidate targets CD16 activation to treat hematologic malignancies. GT Biopharma partners with the National Cancer Institute and other academic institutions for research (per SEC filings, 2023). GT Biopharma has not disclosed team size or AUM. The firm maintains no known adjacent vehicles. As of 2025, it continues to advance its pipeline through Phase 1/2 trials, with no revenue from approved products. The structural differentiator is its public-company status: GT Biopharma trades on the NASDAQ under ticker GTBP. This allows capital access via equity markets, distinct from private biotechs.
General information
Firm type
other
Year founded
1997
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Principals
Anthony Cataldo
Chief Executive Officer
Dr. Raymond Urbanski
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs GT Biopharma?
Anthony Cataldo serves as CEO. Dr. Raymond Urbanski is Chief Medical Officer (per SEC filings, 2023).
What is GT Biopharma's drug pipeline?
The lead candidate GTB-3550 is a bispecific NK cell engager targeting CD16 and CD33 for acute myeloid leukemia and high-risk myelodysplastic syndromes, currently in Phase 1/2 trials (per SEC filings, 2024).
Is GT Biopharma publicly traded?
Yes, the firm trades on the NASDAQ under ticker GTBP (public record).
Does GT Biopharma generate revenue?
No, as a clinical-stage biotech, it has no approved products; revenue is minimal (per SEC filings, 2024).
How is GT Biopharma funded?
Funding comes from public equity markets and occasional financings (per SEC filings, 2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: